Source: Protagonist Therapeutics, Inc. & reported by http://www.prnewswire.com/
MILPITAS, Calif., May 17, 2016 /PRNewswire/ -- Protagonist Therapeutics, Inc. today announced that the company will present new preclinical data on the company's oral peptide drug candidates for inflammatory bowel disease (IBD), PTG-100 and PTG-200, at Digestive Disease Week 2016 (DDW). PTG-200, a first-in-class, IL-23 oral peptide receptor antagonist, will be the subject of an oral presentation, and PTG-100, an alpha-4-beta-7 integrin-specific oral peptide antagonist, will be the subject of a poster presentation.
About PTG-100 and PTG 200
PTG-100 is an oral, GI-restricted, alpha-4-beta-7 integrin-specific antagonist peptide currently in Phase 1 clinical trial in normal healthy volunteers, and is being developed initially for potential treatment of moderate-to-severe ulcerative colitis (UC). The integrin pathway is considered to be one of the most specific biological mechanisms for IBD.
PTG-200 is a first-in-class oral, GI-restricted, Interleukin 23 receptor (IL-23R) antagonist peptide that is being developed initially for potential treatment of moderate-to-severe CD. PTG-200 is currently in Investigational New Drug (IND) enabling studies.
PTG-100 and PTG-200 are derived from Protagonist's proprietary peptide technology platform, and they have the potential of offering oral targeted therapy treatment option for IBD. Protagonist believes PTG-100 and PTG-200 have the potential to transform the existing IBD treatment paradigm because of improved convenience and patient compliance, and potentially improved tolerability compared to injectable antibody drugs.
Read more: http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-new-data-for-ptg-100-and-ptg-200-at-digestive-disease-week-2016-300269736.html